Pramlintide reduces postprandial glucose excursions when added to regular insulin or insulin lispro in subjects with type 1 diabetes: a dose-timing study.

Weyer C, Gottlieb A, Kim DD, Lutz K, Schwartz S, Gutierrez M, Wang Y, Ruggles JA, Kolterman OG, Maggs DG

Diabetes care1 Nov 2003Cited by 69 (Europe PMC)

PMID14578242DOI10.2337/diacare.26.11.3074PepBankPUB-14578242

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study6

6 results from studies that gave the peptide. 6 results from people.

01HumanRandomized controlled trialEfficacy outcome
In type 1 diabetes, only pramlintide injections at -15 or 0 minutes prevented the initial glucose surge, unlike injections after meals.
In plain wordsIn type 1 diabetes, pramlintide before or at meals prevented the initial glucose surge, unlike injections after meals.
Peptide
Pramlintide (Symlin)
Outcome
MixedInitial postprandial glucose surge
Study
n = 40
Comparator
Postprandial pramlintide injections
Outcome group
Glycemic control · Metabolic and weight
Studied dose
60 microg · subcutaneousAs given in this study (human).
Source sentences
Summary
However, only preprandial injections of pramlintide (-15 and 0 min) were able to prevent the initial postprandial surge in glucose.
2 context sentences(design, population, supporting numbers)
Summary · context
In this randomized, single-blind, placebo-controlled, five-way crossover study, 19 subjects with type 1 diabetes using regular insulin and 21 subjects with type 1 diabetes using insulin lispro underwent five consecutive mixed meal tests.
Summary · context
In randomized order, subjects received subcutaneous injections of placebo at -15 min or 60 microg pramlintide at -15, 0, +15, or +30 min relative to the meal after an overnight fast.
Report a problemFND-1457824203
02HumanRandomized controlled trialSafety outcome
In the type 1 diabetes crossover study of pramlintide, no serious adverse events were reported.
In plain wordsIn the type 1 diabetes study of pramlintide, no serious adverse events were reported.
Peptide
Pramlintide (Symlin)
Outcome
Not applicableSerious adverse events
Study
n = 40
Outcome group
Adverse events · Whole body
Studied dose
60 microg · subcutaneousAs given in this study (human).
Source sentences
Summary
No serious adverse events were reported.
2 context sentences(design, population, supporting numbers)
Summary · context
In this randomized, single-blind, placebo-controlled, five-way crossover study, 19 subjects with type 1 diabetes using regular insulin and 21 subjects with type 1 diabetes using insulin lispro underwent five consecutive mixed meal tests.
Summary · context
In randomized order, subjects received subcutaneous injections of placebo at -15 min or 60 microg pramlintide at -15, 0, +15, or +30 min relative to the meal after an overnight fast.
Report a problemFND-1457824206
03HumanRandomized controlled trialEfficacy outcome
In type 1 diabetes using insulin lispro, pramlintide at all four injection times reduced glucose excursions versus placebo.
In plain wordsIn type 1 diabetes using lispro, pramlintide at all tested times reduced glucose rises after meals versus placebo.
Peptide
Pramlintide (Symlin)
Outcome
DecreasePostprandial glucose excursion with lispro
Study
n = 21
Comparator
Placebo with insulin
Outcome group
Glycemic control · Metabolic and weight
Studied dose
60 microg · subcutaneousAs given in this study (human).
Measurements
Reduction in postprandial incremental AUC(0-4 h) vs placebo
36 to 100%
insulin lispro group; range reported as 36 to >100% across the four pramlintide injection times, both insulin groups reported together
Source sentences
Summary
In both the regular insulin and insulin lispro groups, pramlintide injections at all four time points lowered the postprandial glucose excursion (36 to >100% reduction in incremental area under the concentration time curve from 0 to 4 h (AUC(0-4 h)) compared with placebo.
2 context sentences(design, population, supporting numbers)
Summary · context
In this randomized, single-blind, placebo-controlled, five-way crossover study, 19 subjects with type 1 diabetes using regular insulin and 21 subjects with type 1 diabetes using insulin lispro underwent five consecutive mixed meal tests.
Summary · context
In randomized order, subjects received subcutaneous injections of placebo at -15 min or 60 microg pramlintide at -15, 0, +15, or +30 min relative to the meal after an overnight fast.
Report a problemFND-1457824202
04HumanRandomized controlled trialEfficacy outcome
In type 1 diabetes, mealtime pramlintide reduced glucose excursions by 75% versus insulin lispro plus placebo.
In plain wordsIn type 1 diabetes, mealtime pramlintide reduced glucose rises after meals versus insulin lispro plus placebo.
Peptide
Pramlintide (Symlin)
Outcome
DecreaseGlucose excursion at mealtime injection with lispro
Study
n = 21
Comparator
Placebo with insulin
Outcome group
Glycemic control · Metabolic and weight
Studied dose
60 microg · subcutaneousAs given in this study (human).
Measurements
Postprandial glucose excursion reduction vs insulin lispro plus placebo
75%
pramlintide at 0 min, insulin lispro
Incremental AUC(0-4 h)
2.5 mmol x h(-1) x l(-1)
pramlintide at 0 min plus insulin lispro
Incremental AUC(0-4 h)
10 mmol x h(-1) x l(-1)
placebo plus insulin lispro
Source sentences
Summary
and by 75% compared with insulin lispro plus placebo (incremental AUC(0-4 h): 2.5 +/- 2.1 vs. 10.0 +/- 2.5 mmol x h(-1) x l(-1), P < 0.0098).
2 context sentences(design, population, supporting numbers)
Summary · context
In this randomized, single-blind, placebo-controlled, five-way crossover study, 19 subjects with type 1 diabetes using regular insulin and 21 subjects with type 1 diabetes using insulin lispro underwent five consecutive mixed meal tests.
Summary · context
In randomized order, subjects received subcutaneous injections of placebo at -15 min or 60 microg pramlintide at -15, 0, +15, or +30 min relative to the meal after an overnight fast.
Report a problemFND-1457824205
05HumanRandomized controlled trialEfficacy outcome
In type 1 diabetes using regular insulin, pramlintide at all four injection times reduced glucose excursions versus placebo.
In plain wordsIn type 1 diabetes using regular insulin, pramlintide at all tested times reduced glucose rises after meals versus placebo.
Peptide
Pramlintide (Symlin)
Outcome
DecreasePostprandial glucose excursion with regular insulin
Study
n = 19
Comparator
Placebo with insulin
Outcome group
Glycemic control · Metabolic and weight
Studied dose
60 microg · subcutaneousAs given in this study (human).
Measurements
Reduction in postprandial incremental AUC(0-4 h) vs placebo
36 to 100%
regular insulin group; range reported as 36 to >100% across the four pramlintide injection times, both insulin groups reported together
Source sentences
Summary
In both the regular insulin and insulin lispro groups, pramlintide injections at all four time points lowered the postprandial glucose excursion (36 to >100% reduction in incremental area under the concentration time curve from 0 to 4 h (AUC(0-4 h)) compared with placebo.
2 context sentences(design, population, supporting numbers)
Summary · context
In this randomized, single-blind, placebo-controlled, five-way crossover study, 19 subjects with type 1 diabetes using regular insulin and 21 subjects with type 1 diabetes using insulin lispro underwent five consecutive mixed meal tests.
Summary · context
In randomized order, subjects received subcutaneous injections of placebo at -15 min or 60 microg pramlintide at -15, 0, +15, or +30 min relative to the meal after an overnight fast.
Report a problemFND-1457824201
06HumanRandomized controlled trialEfficacy outcome
In type 1 diabetes, mealtime pramlintide reduced glucose excursions by >100% versus regular insulin plus placebo.
In plain wordsIn type 1 diabetes, mealtime pramlintide reduced glucose rises after meals versus regular insulin plus placebo.
Peptide
Pramlintide (Symlin)
Outcome
DecreaseGlucose excursion at mealtime injection with regular insulin
Study
n = 19
Comparator
Placebo with insulin
Outcome group
Glycemic control · Metabolic and weight
Studied dose
60 microg · subcutaneousAs given in this study (human).
Measurements
Postprandial glucose excursion reduction vs regular insulin plus placebo
> 100%
pramlintide at 0 min, regular insulin
Incremental AUC(0-4 h)
−0.6 mmol x h(-1) x l(-1)
pramlintide at 0 min plus regular insulin
Incremental AUC(0-4 h)
11 mmol x h(-1) x l(-1)
placebo plus regular insulin
Source sentences
Summary
The optimal time for pramlintide injection was 0 min, which reduced the postprandial glucose excursion by >100% compared with regular insulin plus placebo (incremental AUC(0-4 h): -0.6 +/- 2.5 vs. 11.0 +/- 2.9 mmolx h(-1) x l(-1), P < 0.0007)
2 context sentences(design, population, supporting numbers)
Summary · context
In this randomized, single-blind, placebo-controlled, five-way crossover study, 19 subjects with type 1 diabetes using regular insulin and 21 subjects with type 1 diabetes using insulin lispro underwent five consecutive mixed meal tests.
Summary · context
In randomized order, subjects received subcutaneous injections of placebo at -15 min or 60 microg pramlintide at -15, 0, +15, or +30 min relative to the meal after an overnight fast.
Report a problemFND-1457824204

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
22 Oct 2026, 02:26 UTC
Study results updated
Version 1
21 Oct 2026, 18:59 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.